Company: INMB
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001213900-25-073077
Chunk: 50

Company: Inmune Bio, Inc.
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 1
Chunk 50
---
 Kelly Ganjei, an existing member of the Board, as Chairman of the Board, effective as of the Effective Date. Mr. Ganjei has
served on the Board since September 2016 and brings extensive leadership and industry experience to the role of Chairman. Mr. Ganjei will
hold office until the election and qualification of a successor or until either individual’s earlier death, resignation or removal.

Appointment of New President,
Chief Executive Officer and Member of the Board 

On August 4, 2025, the Board
appointed David J. Moss, who was then serving as the Company’s Chief Financial Officer, Treasurer and Secretary, as President, Chief
Executive Officer and as a member of the Board, effective as of the Effective Date. On the same date, the Board also appointed Mr. Moss
as the Company’s Principal Executive Officer, effective immediately. In connection with these appointments, Mr. Moss resigned as
Chief Financial Officer, effective immediately. The Principal Executive Officer position will terminate as of the Effective Date, upon
the effectiveness of Mr. Moss’s appointment as President, Chief Executive Officer and as a member of the Board.

Mr. Moss, age 55, is a co-founder
and has been the Chief Financial Officer since the Company’s formation in September 2015. He also serves as Secretary and Treasurer
and from September 15, 2015 until April 2018, Mr. Moss was also a member of the Board. Mr. Moss was audit committee chair for Qilian International
Holding Groups LTD. from December 2020 to February 2022 and served as a director and audit committee chair of Xiangtai Food Co from Aug
2019 to Aug 2020 and was a director of Pegasi Energy Resources Corporation from May 2007 to January 2014 and was a founding investor in
Reliant Service Group LLC which sold in 2015 to a leading private equity firm. From 1996 until 2001 he served as Managing Partner at a
Seattle based venture capital firm, The Phoenix Partners. From November 2010 until October 2011, Mr. Moss was the Chief Executive Officer,
sole director and a majority shareholder of Tamandare Explorations Inc. a private specialty pharmaceutical company. In October 2011 Tamandare
Explorations engaged in a merger transaction pursuant with Tonix Pharmaceuticals Holding Corp., which at the time had its common stock
listed on the OTC Bulletin Board and is currently listed on Nasdaq